Author:
Weng L.,Ziliak D.,Im H.K.,Gamazon E.R.,Philips S.,Nguyen A.T.,Desta Z.,Skaar T.C.,Flockhart D.A.,Huang R.S.
Funder
University of Chicago Cancer Center
National Institutes of Health/National Institute of General Medical Science
Consortium on Breast Cancer Pharmacogenomics
National Institute of General Medical Science K08
National Cancer Institute R21
University of Chicago Breast Cancer SPORE Career Development Award
National Center for Advancing Translational Sciences of the National Institutes of Health
Reference23 articles.
1. Tamoxifen treatment for breast cancer: concept to gold standard;Jordan;Oncology (Williston Park),1997
2. Cellular and molecular pharmacology of antiestrogen action and resistance;Clarke;Pharmacol Rev,2001
3. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment;Jin;J Natl Cancer Inst,2005
4. SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen;Moyer;Pharmacogenomics,2011
5. The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients;van Schaik;Pharmacogenomics,2011
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献